Sildenafil Citrate Tablet, Film Coated
Product Images NDC 43063-941

10 FDA label images from Pd-rx Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 43063-941). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

43063941 Label (43063941)

43063941 Label (43063941)
Label for Sildenafil USP 50 mg tablets, containing 15 tablets per bottle. The label displays the NDC 43063-941-15 and identifies PD-Rx Pharmaceuticals, Inc. as the labeler. It includes a warning to keep out of reach of children and advises to follow dosage and storage instructions from the package insert. The expiration date shown is 09/2020 with lot number D20C41.*
FDA Label Image

Chemical Structure

Chemical Structure
Chemical structure diagram of sildenafil citrate, showing its detailed molecular composition with labeled atomic groups and bonds.*
FDA Label Image

Figure 1

Figure 1
A line graph displaying the change in systolic blood pressure (mmHg) over time (hours) from pre-dose to 24 hours post-dose. Two treatment groups are compared: Sildenafil 100 mg and Placebo. The x-axis represents time post-dose in hours, and the y-axis represents systolic blood pressure changes.*
FDA Label Image

Figure 2

Figure 2
A line graph showing change in systolic blood pressure (SBP) in mmHg over 8 hours postdose. It compares the effects of Doxazosin with Placebo (gray line) and Doxazosin with Sildenafil 25 mg (black line), displaying greater SBP reduction with the combination including Sildenafil.*
FDA Label Image

Figure 3

Figure 3
A line graph depicting the change in systolic blood pressure (SBP) in mmHg over time postdose (hours) for two treatments: Doxazosin + Placebo and Doxazosin + Sildenafil 50 mg. The graph shows SBP changes from 0 to 8 hours after dosing, with two distinct trend lines representing each treatment group's blood pressure response.*
FDA Label Image

Figure 4

Figure 4
A line graph displaying blood pressure changes in mmHg over 8 hours after dosing. It compares two treatments: Doxazosin combined with Sildenafil 100 mg and Doxazosin combined with placebo, showing trends of blood pressure measurements at various time points post-dose.*
FDA Label Image

Figure 5

Figure 5
A line graph depicting plasma concentrations (ng/ml) of sildenafil over time (hours) post dose, showing data for a commercial tablet formulation. Plasma concentration peaks sharply before declining gradually over 24 hours.*
FDA Label Image

Figure 6 1

Figure 6 1
Bar chart illustrating the percentage of patients at endpoint by baseline score for a clinical study. The x-axis represents baseline scores ranging from 0 to 5, and the y-axis shows the percentage of patients. Different shaded bars correspond to endpoint scores from 0 to 5, indicating distribution changes across baseline scores.*
FDA Label Image

Figure 6 2

Figure 6 2
A horizontal bar graph showing the percentage of patients at endpoint categorized by baseline scores ranging from 0 to 5. Multiple grouped bars in different shades represent distinct data categories or groups, displayed as percentages on the y-axis versus baseline score on the x-axis. A legend on the right identifies six groups labeled 0 through 5.*
FDA Label Image

Figure 7

Figure 7
A bar chart showing the percentage of patients reporting improvement with different treatments. The bars represent placebo and sildenafil citrate at doses 25 mg, 50 mg, and 100 mg, with increasing percentages of improvement from 24% for placebo to 82% for sildenafil citrate 100 mg. The chart includes sample sizes for each group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.